Connect Biopharma, a Suzhou-San Diego company, raised $191 million in a NASDAQ IPO to support its portfolio of autoimmune treatments. The company's lead candidate, CBP-201, is an antibody that targets interleukin-4 receptor alpha for inflammatory diseases such as atopic dermatitis (AD) and asthma. It is being tested in Phase II trials in the US , Australia and New Zealand . In initial trading, Connect moved 22% higher, giving the company a market cap of $1.2 billion. More details.... Stock Symbol: (NSDQ: CNTB) Share this with colleagues: // //